NOV 17, 202652 MINS READ
The microbial production of Creatine Phosphate via enzymatic catalysis has emerged as a green alternative to chemical synthesis, yet introduces specific microbiological quality challenges. Recombinant Escherichia coli strains such as BL21(DE3)-pET21a(+)-CPK have been engineered to express high-activity creatine kinase, achieving enzyme activities up to 30 U/g wet cell mass and crude lysate activities of approximately 6 U/mL 1. In this system, creatine (10 g/L) and adenosine triphosphate (ATP, 7.5 g/L) are converted to Creatine Phosphate in the presence of 65 mmol/L magnesium sulfate at pH 9.0 and 37°C over 3 hours, with optimal enzyme loading at 450 U/L 1. While this bioprocess offers mild reaction conditions and simplified downstream purification compared to multi-step chemical routes, the use of live microbial biomass or cell lysates necessitates rigorous control of residual viable cells, endotoxins, and enzymatic by-products.
Microbial contamination risks in fermentation-derived Creatine Phosphate arise from several sources:
To mitigate these risks, manufacturers implement multi-barrier strategies including sterile filtration (0.22 μm), chromatographic polishing (anion exchange to remove nucleic acids and HCP), and validated viral inactivation steps (e.g., low-pH hold at pH 3.5 for 1 hour), even though bacterial fermentation does not inherently carry viral risk 1.
Several microbial genera—Brevibacterium, Corynebacterium, Pseudomonas, and Arthrobacter—produce creatinine desiminase (creatinine iminohydrolase), which catalyzes the hydrolysis of creatinine to N-methylhydantoin and ammonia 2,6. Although these organisms are not typically employed in Creatine Phosphate synthesis, their enzymatic activities are relevant to quality control: residual creatinine (a cyclization product of creatine) in Creatine Phosphate raw materials can be degraded by contaminating microorganisms during storage or formulation, leading to ammonia accumulation and pH drift. Creatinine desiminase from Pseudomonas or Brevibacterium exhibits optimal activity at pH 7–8 and 30–37°C, conditions that overlap with typical pharmaceutical storage environments 2,6.
Analytical methods to detect such microbial enzyme activities include:
Manufacturers must validate that total aerobic microbial count (TAMC) remains ≤10² CFU/g and total yeast and mold count (TYMC) ≤10¹ CFU/g per Ph. Eur. 2.6.12 for non-sterile solid dosage forms, or achieve sterility (zero CFU in 20 units tested) for injectable Creatine Phosphate per USP <71> 13.
Optimized fermentation protocols for creatine kinase production directly influence downstream microbial burden. A two-phase fed-batch strategy has been reported for creatinine iminohydrolase (a related enzyme) production in aerobic soil microorganisms, which serves as a model for Creatine Phosphate enzyme fermentation 8,11:
Phase 1 (Batch growth on ammonia):
Phase 2 (Nitrogen-limited fed-batch with creatinine induction):
Critical microbial limit controls during fermentation include:
Post-fermentation, cells are harvested by centrifugation (8,000 × g, 20 min, 4°C) and lysed via ultrasonication (20 kHz, 50% duty cycle, 10 min on ice) or high-pressure homogenization (1,000–1,500 bar, 3 passes) 3,18. The lysate is clarified by centrifugation (15,000 × g, 30 min) and subjected to sterile filtration (0.45 μm pre-filter, 0.22 μm final filter) to remove residual cells and reduce bioburden to <10 CFU/100 mL prior to chromatographic purification 3.
High-performance liquid chromatography with evaporative light-scattering detection (HPLC-ELSD) has been validated for quantifying inorganic phosphate and organic impurities in disodium Creatine Phosphate, which is critical for assessing microbial phosphatase activity 13. Microbial alkaline phosphatases can hydrolyze Creatine Phosphate to creatine and inorganic phosphate, reducing potency and generating a degradation marker. The HPLC-ELSD method employs:
Complementary microbiological assays include:
For creatinine and creatine quantification (to assess microbial enzymatic degradation), enzymatic endpoint assays using purified creatinine amidohydrolase and creatine amidinohydrolase are employed 3,4,18. These enzymes, produced from Alcaligenes sp. or Penicillium sp., convert creatinine to creatine (K_m ~25 mM at pH 8.0, 37°C) and creatine to sarcosine + urea (K_m ~20 mM) 16,18. Coupled with urease and glutamate dehydrogenase, the released ammonia is quantified spectrophotometrically at 340 nm (NADH oxidation), enabling detection limits of 0.01 mM creatinine/creatine 2,6.
Creatine Phosphate is marketed in multiple dosage forms—injectable solutions (e.g., 1 g/5 mL ampoules for IV infusion in acute myocardial infarction), oral tablets (enteric-coated to enhance absorption), and topical formulations—each with distinct microbial limit specifications 9.
Enteric-coated Creatine Phosphate formulations (designed to resist gastric acid and release in the intestine, thereby improving bioavailability) must additionally meet dissolution specifications (e.g., <10% release at pH 1.2 after 2 hours, >80% release at pH 6.8 after 1 hour post-acid stage) and demonstrate microbial stability over 24-month shelf life at 25°C/60% RH 9.
When microbial-derived enzymes (e.g., creatine kinase) are used as processing aids, residual enzyme activity must be validated as inactive in the final product. ICH Q6B recommends:
Manufacturers must provide a detailed description of the microbial strain (deposited in a recognized culture collection, e.g., ATCC, DSM), fermentation history, and genetic stability data (e.g., plasmid retention over 50 generations) in regulatory submissions (CTD Module 3.2.S.2.3) 1,7.
Microbial contamination can accelerate Creatine Phosphate degradation through enzymatic and non-enzymatic pathways:
Alkaline phosphatases from E. coli, Bacillus spp., and Pseudomonas spp. catalyze:
Creatine Phosphate + H₂O → Creatine + Inorganic Phosphate
Optimal activity occurs at pH 8–10 and 37°C, with K_m values of 0.1–1 mM for Creatine Phosphate 17. In contaminated solutions stored at room temperature, phosphate liberation can reach 5–10% per week, detectable by HPLC-ELSD as increased inorganic phosphate peak area 13.
Creatine spontaneously cyclizes to creatinine at acidic pH (<6) and elevated temperature (>40°C):
Creatine
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| TIANJIN QIREN MEDICAL TECHNOLOGY CO. LTD. | Green enzymatic biosynthesis of pharmaceutical-grade Creatine Phosphate for injectable formulations in acute myocardial infarction treatment and quality-controlled production requiring TAMC ≤10² CFU/g and endotoxin <0.5 EU/mg per regulatory standards. | Enzymatic Creatine Phosphate Production System | Recombinant E. coli BL21(DE3)-pET21a(+)-CPK achieves creatine kinase activity of 30 U/g wet cell mass and crude lysate activity of 6 U/mL, enabling mild reaction conditions (pH 9.0, 37°C, 3 hours) with simplified downstream purification and reduced impurities compared to multi-step chemical synthesis. |
| KYOWA HAKKO KOGYO CO. LTD. | Analytical quality control for detecting microbial enzymatic degradation in Creatine Phosphate raw materials during storage, preventing ammonia accumulation and pH drift that compromise product stability in pharmaceutical manufacturing and sterility testing per USP <71>. | Creatinine Desiminase Enzyme Production | Aerobic fermentation of Brevibacterium, Corynebacterium, Pseudomonas and Arthrobacter genera produces creatinine desiminase with optimal activity at pH 7-8 and 30-37°C, catalyzing creatinine hydrolysis to N-methylhydantoin and ammonia for rapid quantitative determination. |
| BOEHRINGER MANNHEIM G.M.B.H. | Enzymatic endpoint assays for quantifying creatinine and creatine impurities in Creatine Phosphate products to assess microbial contamination and validate compliance with Ph. Eur. 2.6.12 microbial limits (TAMC ≤10³ CFU/g, TYMC ≤10² CFU/g) for non-sterile oral dosage forms. | Creatinine/Creatine Amidohydrolase Enzyme System | Purified creatinine amidohydrolase from Alcaligenes sp. and Penicillium sp. exhibits Km ~25 mM at pH 8.0, 37°C for creatinine-to-creatine conversion, coupled with creatine amidinohydrolase (Km ~20 mM) enabling spectrophotometric detection limits of 0.01 mM via NADH oxidation at 340 nm. |
| EASTMAN KODAK COMPANY | Industrial-scale production of urease-free creatinine iminohydrolase from aerobic soil microorganisms with validated bioburden control (<10³ CFU/mL in-process) and sterile filtration (0.22 μm) to meet ICH Q6B guidelines for residual enzyme activity <0.01 U/mg and host cell DNA <10 ng/dose in Creatine Phosphate manufacturing. | Two-Phase Fed-Batch Creatinine Iminohydrolase Fermentation Process | Nitrogen-limited fed-batch fermentation with creatinine feed at 1.0-1.5 g/L/h and pH control via α-ketoglutaric acid (373 g/L solution) achieves enzyme titers of 6-10 U/mL crude lysate while preventing substrate inhibition and maintaining endotoxin <1 EU/mL for downstream purification to pharmaceutical specifications. |
| SHANGHAI HUATUO MEDICAL SCIENCE CO. LTD. | Quality control of Creatine Phosphate disodium salt intermediates and final products to monitor microbial phosphatase contamination (from E. coli, Bacillus, Pseudomonas spp.) that accelerates degradation at 5-10% per week at room temperature, ensuring potency retention and compliance with injectable sterility requirements (zero CFU per USP <71>). | HPLC-ELSD Impurity Detection Method for Disodium Creatine Phosphate | Reversed-phase C18 HPLC with evaporative light-scattering detection at 40°C achieves sensitivity of 0.1% w/w for inorganic phosphate (LOD 0.05 mg/mL, LOQ 0.15 mg/mL) with linearity r²>0.999 and precision RSD <2%, enabling detection of microbial alkaline phosphatase activity that hydrolyzes Creatine Phosphate to creatine and phosphate. |